Integrating computational pathology and multi-transcriptomics to characterize glioblastoma heterogeneity and identify prognostic biomarkers
{{output}}
Background: Glioblastoma (GBM) remains a lethal brain cancer with median survival of 12-15 months, hindered by pronounced heterogeneity. Integrating histopathological, molecular, and microenvironmental data is critical for improv... ...
